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Aim: To investigate the diagnostic value of plasma-free DNA concentration (PF-DNA) in septic patients compared to nonseptic patients
and to correlate it with clinical outcome.
Materials and methods: Forty-two mechanically ventilated consecutive patients (11 septic, 31 nonseptic) admitted to the intensive care
unit (ICU) were recruited. On admission, besides PF-DNA concentration, APACHE II and SOFA scores and serum C-reactive protein
(CRP), procalcitonin (PCT), and serum lipid concentrations, together with clinical outcome, were assessed. Plasma samples from 11
volunteers were also collected. Appropriate statistics were used for analysis.
Results: Median PF-DNA concentrations on admission were significantly higher in septic patients compared to nonseptic patients
[14,285 (48–180,311) GE/mL versus 546.5 (0–7674) GE/mL, P < 0.0001]. For distinguishing septic and nonseptic patients on admission,
the area under the curve obtained for PF-DNA concentration was 0.9 (sensitivity 84%, specificity 95%; cutoff 4083 GE/mL). There
were no significant differences between PF-DNA concentrations of nonsurvivors and survivors. Additionally, DNA concentration
demonstrated a significant correlation with CRP, PCT, and high-density lipoprotein concentrations.
Conclusion: Plasma DNA seems to be a potentially valuable tool to confirm sepsis diagnosis upon ICU admission.
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1. Introduction
Despite increasing knowledge regarding their
pathophysiology as well as new therapeutic strategies and
new-generation antibiotics, sepsis and septic shock remain
the leading causes of death in critically ill patients (1,2).
The overall mortality rate associated with severe sepsis is
still as high as 30% to 50% (3). Mortality rate and outcome
are closely related to early diagnosis and treatment,
along with meticulous follow-up. Thus, early and correct
prediction of sepsis and its outcome are important factors
in modern health management. Several biomarkers, such
as interleukins, procalcitonin (PCT), C-reactive protein
(CRP), fibronectin, and haptoglobin, and some scoring
systems have been evaluated to predict prognosis in
patients with sepsis and its sequel, but none have proved
entirely useful (4).
Nevertheless, data retrieved on nucleic acids as a
possible noninvasive diagnostic and prognostic biomarker
have opened up a new research interest for several clinical
conditions (5). Recently, increased concentration of
plasma-free plasma DNA (PF-DNA) has been shown in
* Correspondence: basakceyda@hotmail.com
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various clinical situations including cancer, trauma, burns,
myocardial infarction, acute stroke, and maternal blood
(6–11). Accordingly, current studies have focused on PFDNA concentration as a tool for diagnosis and follow-up
of these situations, and as a prognostic marker for outcome
as well as prenatal genetic diagnosis (6–9,11). However, its
predictive value is arguable for these circumstances.
Theoretically, PF-DNA can be defined as acellular
DNA fragments detectable in the extracellular fluid. Very
low levels are present in normal, healthy populations. It
has been suggested that DNA enters into the circulation
following cell death, which can be as a result of cell necrosis
or apoptosis, although the exact mechanism is yet not
clear (8,12). Circulating DNA has a short half-life and is
removed mainly by the liver. Accumulation of DNA in the
circulation can result from either an excessive release of
DNA caused by massive cell death or inefficient removal,
or a combination of both.
Sepsis is associated with cell necrosis and apoptosis,
and recently PF-DNA concentrations have also been
shown to be increased in patients with sepsis (7,8,13).
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Furthermore, preliminary data from critically ill intensive
care unit (ICU) patients have suggested that PF-DNA
concentrations measured on admission were higher in
nonsurvivors than in survivors (7,8).
The primary aim of this study was to evaluate the
prognostic and diagnostic value of PF-DNA concentrations
in mechanically ventilated patients with sepsis, severe
sepsis, and septic shock. The secondary aim was to evaluate
the correlation between PF-DNA and different markers
(PCT, CRP, serum lipid levels, and scoring systems)
already used to predict prognosis in patients with sepsis
and its sequel.
2. Materials and methods
Forty-two consecutive patients with systemic inflammatory
response syndrome (SIRS) or sepsis, admitted to the
mixed ICU of our tertiary care hospital, were enrolled in
the study after obtaining local ethics committee approval
and informed consent from patients or their relatives.
Patients who were younger than 18 years of age, pregnant,
immunosuppressed, diagnosed with malignancy or genetic
disease, or admitted because of acute drug overdose were
excluded.
All patients were mechanically ventilated. The
diagnoses of SIRS, sepsis, severe sepsis, and septic shock
were established according to the definition of the
American College of Chest Physicians/Society of Critical
Care Medicine Consensus Conference and evidence-based
management was performed (14).
Determination of PF-DNA concentrations, PCT, CRP,
and other laboratory parameters were performed from
peripheral venous blood. For that, venous blood samples
were taken on admission as soon as possible. In addition to
this, blood samples were collected from 11 healthy subjects
(control group) to determine the PF-DNA concentrations.
Sequential Organ Failure Assessment (SOFA), Simplified
Acute Physiology Score (SAPS), and Acute Physiology and
Chronic Health Evaluation (APACHE II) scores were also
calculated simultaneously with blood sampling.
Furthermore, age, sex, body weight, reason for
admission, clinical diagnosis, and the length of ICU and
hospital stay, as well as ICU, hospital, and 28-day ICU
mortality data, were recorded.
Peripheral venous blood samples (4 mL) were collected
into tubes containing ethylenediamine tetraacetic acid for
PF-DNA evaluation. All blood samples were separated
within 3 h of venesection. Plasma samples were stored
at –20 °C until further processing. Cell-free plasma was
prepared as described by Rhodes et al. (8).
DNA isolation from plasma samples was performed by
phenol/chloroform extractions. PF-DNA was measured
with a real-time PCR assay for the β-goblin gene, which is
present in all nucleated cells of the body. For quantitative
results, human genomic DNA was used to perform a

plasma DNA curve. The unit “genome-equivalents/mL”
was used. One genome-equivalent was defined as the
amount of a particular target sequence contained in a
single diploid human cell (6).
The nephelometric method (Dade-Behring) for plasma
CRP and Kryptor assay (B.R.A.H.M.S. Diagnostica, Berlin,
Germany) for PCT measurements were used.
Data were expressed as mean ± standard deviation
(SD), median and interquartile range, and number
of patients. Differences in continuous variables were
compared with the nonparametric Mann–Whitney U test
and Kruskal–Wallis tests. Spearman’s rho correlation tests
were used for correlation analysis and receiver operating
characteristic (ROC) analysis was used for plasma-free
DNA concentration, PCT, CRP, and SOFA score as a
predictor of sepsis in patients admitted to the ICU. A
univariate analysis was performed to compare various
parameters (age; PF-DNA concentration; SOFA, SAPS,
and APACHE II scores; PCT, CRP, and HDL levels) as
predictors of mortality on admission. Logistic regression
analysis was performed to identify factors that had
independent predictive value for ICU mortality. Statistical
analysis was performed with SPSS 12.0 (SPSS Inc., Chicago,
IL, USA). P < 0.05 was considered significant.
3. Results
Forty-two mechanically ventilated ICU patients were
recruited into the study. From these 42 patients, 31 were
nonseptic and 11 were septic. Demographic data are
presented in Table 1. Additionally, primary infectious
sources and sites and causative organisms of the 11 septic
patients are presented in Table 2. On admission to the
ICU, the mean APACHE II score was 14.6 ± 6.4 and the
mean SOFA score was 4.9 ± 3.2. The mean length of stay
of patients in the ICU was 25.4 ± 20 days and the mean
length of stay in the hospital was 33.3 ± 27 days. ICU and
hospital mortalities were 26.2% and 33.3%, respectively.
The PF-DNA concentration on admission was
significantly higher in patients admitted to the ICU
compared to the control group [1476 (0–180,311) GE/mL
versus 371 (33–757) GE/mL, P < 0.05] and in the septic
compared to nonseptic ICU patients [14,285 (48–180,311)
GE/mL versus 546.5 (0–7674) GE/mL, P < 0.0001].
There were no statistically significant differences
between PF-DNA concentrations of survivors compared
to nonsurvivors (when comparing 28-day, ICU, and
hospital mortalities). Additionally, there was no significant
correlation between PF-DNA concentration and hospital
and ICU stay.
PF-DNA levels at admission were correlated with CRP
(r = 0.365, P = 0.037), PCT (r = 0.457, P = 0.007), and
high-density lipoprotein (HDL) (r = –0.415, P = 0.015)
concentrations.
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Table 1. Demographic and medical characteristics of patients on admission and sample distribution according to the diagnosis.
Age (years) (mean ± SD)

51.1 ± 18.7

Weight (kg) (mean ± SD)

74.2 ± 10.1

Height (cm) (mean ± SD)

167.8 ± 9.2

Female/male ratio (n = 42)

20/22

Chronic disease (COPD, CAD, CKF, HT, DM, CLF) (n = 42): (+)/(-)

23/19

Admission diagnosis (n): medical/emergency surgery/elective surgery

21/17/4

APACHE II score
SOFA score
SAPS score

On admission (mean ± SD)

14.6 ± 6.4

On admission, related to the diagnosis: NS/S (mean ± SD)

13.19 ± 4.3/17.4 ± 8.2

On admission (mean ± SD)

4.9 ± 3.2

On admission, related to the diagnosis: NS/S (mean ± SD)

4 ± 2.2/5.9 ± 4.5

On admission (mean ± SD)

29.9 ± 12.2

On admission, related to the diagnosis: NS/S (mean ± SD)

27.4 ± 8.3/34.8 ± 15.8

Diagnosis on admission (n = 42): NS/S/SS/Ssh

31/4/6/1

NS: nonseptic; S: septic; SS: severe sepsis; Ssh: septic shock; COPD: chronic obstructive pulmonary disease; CAD: coronary artery
disease; CKF: chronic kidney failure; HT: hypertension; DM: diabetes mellitus; CLF: chronic liver failure.

Patient distribution
Primary source of infections:
Nosocomial

10

Community-acquired

1

Primary site of infections*:
Lung

6

Urinary tract

2

Blood

3

Intraabdominal

3

CNS**

1

Soft tissue

1

Causative organisms ***:
Acinetobacter baumannii

8

Streptococcus pneumoniae

1

MRSA****

1

Staphylococcus aureus

1

Staphylococcus hominis

1

Enterococcus

1

*Five patients had multiple infections in different sites.
**CNS: central nervous system.
***Two patients had polymicrobial infections.
****Methicillin-resistant Staphylococcus aureus.
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ROC curves were constructed to define admission PFDNA concentration as a predictor of sepsis in critically
ill ICU patients. The cut-off value for distinguishing
between septic and nonseptic patients on admission was
4083 GE/mL (95% CI: 0.789–1.021) with 84% sensitivity,
95% specificity, and area under the curve (AUC) of 0.9
(Figure 1). ROC curve analysis of CRP, PCT, HDL, and
SOFA score on admission for the prediction of sepsis are
presented in Figure 2. The AUC for PCT was 0.9 (95% CI:
1.0

PF-DNA

0.8

Sensitivity

Table 2. Primary infectious sources and sites, and causative
organisms of septic patients (n = 11).

0.5

0.3

0.0
0.0

0.3

0.5
1 - Specificity

0.8

1.0

Figure 1. ROC curves for PF-DNA concentration on admission
to the ICU to predict sepsis diagnosis. The area under the curve
for PF-DNA concentration is 0.9 (95% CI: 0.78–1.02).
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Figure 2. ROC curve analysis of CRP, PCT, HDL, and SOFA score for the prediction of sepsis on admission.

0.86–1.00), which was the most similar value to that for
PF-DNA concentration.
Univariate analyses were performed to compare several
parameters as predictors of mortality on admission. Age;
SOFA, SAPS, and APACHE II scores; and PCT and HDL
levels were significantly different between survivors and
nonsurvivors (Table 3).
4. Discussion
The results obtained in this study show that PF-DNA
concentration was significantly higher in critically ill
patients compared to the healthy control group and in
septic compared to nonseptic patients. On admission, PFDNA concentration was positively correlated with CRP
and PCT, while negatively correlated with HDL.

The diagnostic cutoff value for PF-DNA predicting
sepsis was 4083 GE/mL, which was lower than in other
studies. Furthermore, the PF-DNA concentrations of our
patient population were also lower than in other studies.
This discrepancy could be due to the impacts of organ
dysfunctions as well as therapeutic modalities such as
hemodialysis or plasmapheresis during the sampling time.
These factors that were not evaluated in this study could
have affected the PF-DNA clearances.
Recent studies measured PF-DNA concentration of
various critically ill patients on admission to the ICU
and correlated these values with the diagnosis and with
the outcomes (7–9,15–18). Wijeratne et al., Rhodes et al.,
Saukkonen et al., and Huttunen et al. demonstrated that
high PF-DNA levels on admission were related to poor

153

MEÇO et al. / Turk J Med Sci
Table 3. Follow-up parameters on admission for survivors and nonsurvivors in the ICU.
Survivors
(n = 31)

Nonsurvivors
(n = 11)

P-value

47 (16–83)

73 (25–81)

0.020*

SOFA

3 (0–10)

7 (2–17)

0.008*

SAPS

26 (12–42)

36 (20–73)

0.001*

APACHE II

13 (5–25)

17 (11–38)

0.006*

PCT (ng/mL)

0.425 (0.06–40.5)

2.39 (0.15–196.3)

0.019*

CRP (mg/L)

96.4 (9.77–344)

104 (45.1–358)

0.575

24.5 (13–68)

19 (10–50)

0.045*

1475.7 (0–180,311)

1567 (0–67,660)

0.596

Age (years)

HDL (mg/dL)
PF-DNA on admission (GE/mL)

PCT: procalcitonin, CRP: C-reactive protein, HDL: high-density lipoprotein.
Data presented as median with interquartile range. *P < 0.005.

prognosis and organ dysfunction and may be used as a
predictor of mortality and sepsis in critically ill patients
(7–9,19). Our results suggest that sepsis is associated
with higher PF-DNA concentrations than those in
nonseptic patients on admission and in the control
group. These results are in accordance with the results
of previous studies. However, in our study, admission
PF-DNA concentrations were similar among survivors
and nonsurvivors in the ICU, in the hospital and at 28
days. This discrepancy may be due to our relatively small
sample size.
It has been suggested that cell apoptosis may be an
important source of PF-DNA (19–21). Therefore, PF-DNA
may be used as a marker of apoptosis. Furthermore, several
studies comparing status of septic and nonseptic critically
ill patients related to the apoptosis levels have shown
that the quantity of apoptosis was correlated with sepsis
prognosis (22,23). Brinkmann et al. also demonstrated
that neutrophils activated by bacterial endotoxins release
molecular complexes consisting in part of DNA (24).
Consequently, the level of PF-DNA may be correlated
with the diagnosis and prognosis of sepsis in critically ill
patients.
In recent studies, several biomarkers and tools were
discussed to define the most appropriated ones for sepsis
diagnosis and follow-up (25–28). We compared different
biomarkers with PF-DNA concentration values and we
have seen that PF-DNA concentration was positively
correlated with CRP and PCT and negatively correlated
with HDL. Previous studies have also shown correlations
of PF-DNA with several biomarkers (7,16). However, some
studies described no correlation between these markers
(8).
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All of the findings of this study point toward
the importance and possible future use of PF-DNA
concentrations as a reliable noninvasive prognostic
factor in the modern management of septic patients in
ICUs. Nevertheless, this study could be criticized for the
small number of patients and an inconsistent patient
population. Therefore, further studies should be designed
with larger numbers and well-defined patient populations.
Furthermore, multiple sampling from the same patients
can be performed during the ICU stay for the follow-up of
PF-DNA trends and to establish the value of PF-DNA even
more precisely as a new follow-up tool in the critically ill
patient population.
In conclusion, infectious processes and especially sepsis
increase PF-DNA concentrations. PF-DNA concentration
is a diagnostic marker for sepsis in critically ill patients
during the overall ICU and hospital stay. Additionally, it
is correlated with PCT, CRP, and HDL levels. Therefore,
the use of PF-DNA concentration is a relatively simple
and noninvasive rapid marker, which could be correlated
within the current diagnosis and management of critically
ill patients.
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